Prognostic Value of Blasts in Peripheral Blood in Myelofibrosis in the Ruxolitinib Era

BACKGROUND: Peripheral blasts (PB) ≥1% have long been considered an unfavorable feature for patients with primary myelofibrosis (PMF). Whether further quantification of PB blasts and their correlation with bone marrow (BM) blasts has incremental value with regards to patient prognostication is uncle...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer
Glavni autori: Masarova, Lucia, Bose, Prithviraj, Pemmaraju, Naveen, Daver, Naval G., Zhou, Lingsha, Pierce, Sherry, Sasaki, Koji, Kantarjian, Hagop, Estrov, Zeev, Verstovsek, Srdan
Format: Artigo
Jezik:Inglês
Izdano: 2020
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7875207/
https://ncbi.nlm.nih.gov/pubmed/32697338
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.33094
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items